NSG-SGM3 mice highly engrafted with primary FLT3D835Y AML cells from patient 7 (24.5% ± 2.2% human CD33+ cells in PB) (Fig. 3a,b and Supplementary Tables 2 and 3) were treated with TCRFLT3D/Y (n = 7) or control TCR1G4 (n = 6) cells. This evidence concerns the gene CD33 and acute myeloid leukemia.